GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
GeneDx shows strong financial performance with raised revenue and margin guidance and profitability expectations. NICU and pediatrics markets offer significant growth opportunities. While ASPs may decrease, the company is expanding its sales force and partnerships. Despite some uncertainties in short-term revenue from newborn screening, the overall outlook is bolstered by strategic investments and international expansion plans. The Q&A session reinforces positive sentiment with growth in core markets and proactive strategies, leading to an expected positive stock price movement.
Key Financial Performance
Revenue for Q3 2025 $116.7 million, a 52% increase year-over-year. This growth was driven by a 66% increase in revenue from exome and genome testing, which totaled $98.9 million.
Exome and Genome Tests Volume 25,702 tests in Q3 2025, showing an acceleration in growth from 24% year-over-year in Q1 to 33% in Q3. This growth is attributed to increased ordering patterns and expansion into new markets.
Average Reimbursement Rate for Exome and Genome Tests Over $3,500 per test in Q3 2025, up from $3,100 a year ago. The increase is due to improved reimbursement and Medicaid coverage expansion.
Adjusted Gross Margin 74% in Q3 2025, driven by favorable mix shift, improved reimbursement, and lower costs of goods sold (COGS).
Adjusted Total Operating Expenses $71 million in Q3 2025, representing 61% of revenue. The increase is due to strategic investments in sales, marketing, R&D, and international market development.
Adjusted Net Income $14.7 million in Q3 2025, with an adjusted basic EPS of $0.51. This reflects strong demand and operational efficiency.
Cash and Cash Equivalents $156 million as of September 30, 2025. This includes $9 million in free cash flow generated during the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ExomeDx and GenomeDx tests: Received FDA breakthrough device designation, validating their industry-leading technology for transforming lives and shaping the future of health.
GeneDx Infinity: Largest rare disease data set used to generate deep genomic insights for fast and reliable diagnoses, fueling the precision medicine revolution.
Ultra-rapid genome testing: Proves its value for critically ill infants, with potential to scale testing in NICUs.
Pediatricians and NICU market: Expanding into general pediatricians and underpenetrated NICU markets, with plans to double the sales force and integrate into more hospitals.
International markets: Developing markets outside the U.S. with the Fabric genomics platform and local teams.
Revenue growth: Third quarter 2025 revenues reached $116.7 million, a 52% year-over-year increase, with exome and genome revenues up 66%.
Cost optimization: Leveraging automation and AI to reduce costs and improve gross margins, which reached 74% in Q3 2025.
Medicaid coverage expansion: Medi-Cal, the largest state Medicaid program, will begin covering whole genome testing, marking the 36th state to do so.
New executive hires: Appointed Lisa Gurry as Chief Business Officer and Dr. Mimi Lee as Chief Precision Medicine Officer to enhance data diagnostics and partnerships.
Shift to proactive care: Focusing on genomic newborn screening and adult conditions to transition from reactive to proactive personalized care.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company acknowledges that forward-looking statements inherently involve risks and uncertainties, which could cause actual results to materially differ from projections. This includes potential regulatory challenges in expanding coverage and adoption of genetic testing.
Market Penetration Challenges: The company is expanding into new markets, such as general pediatricians and international regions, which may initially have lower reimbursement rates and require significant investment in sales force and education. Adoption in these markets may take 18 to 24 months, posing a risk to short-term revenue growth.
Economic Uncertainties: Investments in new markets and customer experience innovations are expected to impact near-term operating margins. Economic conditions could affect the company's ability to sustain these investments.
Supply Chain and Operational Risks: The company relies on advanced genomic technologies and AI tools, which may face supply chain disruptions or technical challenges, potentially impacting production and service delivery.
Strategic Execution Risks: The company is making deliberate investments in new markets, technologies, and customer experience. Failure to achieve expected ROI or delays in execution could impact long-term growth and profitability.
Competitive Pressures: The company highlights its competitive moat through its GeneDx Infinity data set but acknowledges the need to maintain this advantage against competitors who may develop similar capabilities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Revenue Guidance: GeneDx has raised its 2025 revenue guidance to $425 million to $428 million, reflecting strong momentum and growth.
Exome and Genome Revenue Growth: The company expects exome and genome revenue to grow between 53% and 55% for the full year 2025, translating to $358 million to $361 million. Excluding a discrete benefit from 2024, the growth rate is projected at 57% to 60%.
Exome and Genome Volume Growth: GeneDx reaffirms its expectation of at least 30% exome and genome volume growth for 2025, with a fourth-quarter exit rate of at least 34%.
Adjusted Gross Margin: The company has raised its full-year 2025 adjusted gross margin guidance to between 70% and 71%.
NICU Market Penetration: GeneDx plans to significantly scale testing in Level 3 and Level 4 NICUs over time, with 8 Epic Aura integrations live and at least 12 expected by year-end.
Pediatric Market Expansion: The company is building out its commercial team to target general pediatricians, expecting adoption to take 18 to 24 months from the June 2025 update.
Newborn Screening Initiatives: GeneDx is advancing genomic newborn screening programs, including the GUARDIAN study and partnerships with the NIH Beacon program and Sunshine Genetics Network, aiming for broad adoption to shift from reactive to proactive care.
International Market Development: The company is expanding its presence in key international markets, leveraging the Fabric genomics platform to serve global markets at scale.
AI and Automation in Genomics: GeneDx is investing in AI and automation to optimize production, reduce costs, and improve turnaround times, with the potential to make ultra-rapid genome testing the standard of care.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have you seen an uptick in volume due to the AAP guidelines for clinicians to start with chromosomal microarray?
A:No meaningful uptake in orders from pediatricians for CMA was observed, but there was good engagement and positive feedback from pediatricians about ordering testing from GeneDx. The company is focusing on improving the ordering process and education, expecting results by 2026.
Q:Does the guide imply ASPs to go down sequentially, and are there any seasonal dynamics?
A:The guide implies a potential $100 decrease in ASPs in Q4 due to new call points and target indication expansion. This is a conservative estimate as rates may initially be lower before building experience with payers.
Q:Is the strong margin this quarter sustainable?
A:The company raised the gross margin guide but maintained a conservative stance to account for potential reimbursement rate fluctuations in Q4.
Q:What is the NICU contribution to volume growth, and what feedback has been received?
A:NICU volumes are growing nicely and are one of the fastest-growing channels. The company expects an incremental 2,000 units in the second half of the year, with most in Q4. Feedback has been positive, and the company is on track to activate 12 systems by year-end.
Q:What drove the better-than-expected quarter, and how does it inform the Q4 guide?
A:The strength was driven by core outpatient markets, particularly from Expert Geneticists and pediatric neurologists. The company expects continued growth from these segments and plans to activate more doctors in the coming quarters.
Q:What is the outlook for OpEx spending and its impact on growth?
A:OpEx is expected to increase as the company builds out its commercial team and invests in R&D. The company aims to keep the business profitable while making these investments to achieve long-term growth.
Q:How quickly will the sales force be onboarded, and what is the long-term plan?
A:The company is hiring regional sales directors and expects to double the sales force over the next several quarters. The focus is on accelerating adoption and ensuring proper training and activation of the team.
Q:What is the potential for clinical revenue from newborn genetic screening initiatives?
A:The company does not expect significant revenue from newborn genetic screening in 2026 but aims to accelerate policies for earlier revenue generation. The focus is on building evidence and health economics data.
Q:What is the rationale for pursuing FDA approval for the test?
A:FDA approval is seen as a validation that can accelerate market adoption, especially among pediatricians. The company is leveraging its existing data and processes to expedite the regulatory review.
Q:What is the ROI on investments in sales, brand campaigns, and technology?
A:The investments are aimed at expanding the market beyond the current physician types and improving the customer experience. The company expects these investments to drive long-term growth and maintain a majority market share.
Q:What is the impact of Medi-Cal expansion on revenue and strategy for other states?
A:The Medi-Cal expansion is expected to convert previously unpaid tests into reimbursed ones, with a collection rate of about 80%. The company is using health economics data to advocate for Medicaid coverage in other states.
Q:What is the long-term outlook for pricing and innovation in genetic testing?
A:The company believes that continuous innovation in technology and data will sustain pricing and improve diagnostic yields. Investments in medium and long-read sequencing are expected to enhance the test's value.
Q:What steps are needed to expand into the general pediatrician market?
A:The company is focusing on education, workflow improvements, market access, and building a dedicated sales team. These steps are expected to drive adoption within 18 to 24 months.
Q:What is the competitive advantage of the Infinity database and AI tools?
A:The Infinity database and AI tools improve diagnostic accuracy and efficiency, making the company a leader in the space. These tools also add value for pharma and other partners.
Q:What is the impact of new technologies like medium and long-read sequencing?
A:These technologies improve diagnostic yields and help transition more patients from panels to exome and genome testing, enhancing the overall test quality.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact timing and financial impact of certain initiatives, such as the newborn genetic screening revenue potential and the FDA approval process. Responses were often broad, emphasizing long-term potential without concrete short-term metrics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Academy Pediatrics
American Academy
COGS
Chief Officer
GeneDx Infinity
Infinity disease
Katherine
Level
adoption
biopharma health
brand
care setting
chance
class
clinician patient
condition
customer experience
economy scale
future term
genomics
increase
investment term
minute
network effect
parent
power
precision medicine
product technology
quarter
result today
setting NICU
specialty
speed accuracy
term value
turn
update
variant
world GeneDx
WGS Transcript
GeneDx Holdings Corp. (WGS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
GeneDx Holdings Corp. (WGS) Q1 2026 Earnings Call Transcript
Positive5-4
The financial performance shows strong revenue growth of 25% YoY and improved gross margins, indicating operational efficiency. Despite a net loss, the reduction from the previous year is positive. The reaffirmed revenue guidance for 2026 and market expansion plans into new sectors and geographies suggest optimism. The company's strategic initiatives, such as expanding into new markets and increasing sales force, indicate growth potential. However, the lack of discussion on operational updates and strategic initiatives during the call slightly tempers the positivity, leading to a 'Positive' sentiment.
GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call summary and Q&A indicate strong growth prospects with raised revenue guidance, robust exome and genome revenue growth, and increased adjusted gross margin. The company's strategic initiatives in NICU, pediatrics, and international markets, along with AI and automation investments, further enhance the outlook. Despite some uncertainties in the Q&A, the overall sentiment is positive, supported by optimism in new market penetration and operational efficiency improvements. The absence of negative catalysts like margin decline or guidance cuts solidifies the positive sentiment.
WGS Slides
WGS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
